CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Medpace Holdings, Inc. (MEDP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Medpace Holdings, Inc. (MEDP)

Services-Commercial Physical & Biological Research · market cap $17.6B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
VI-0521Phase 3Obesity
Diazoxide Choline Controlled-Release TabletPhase 2Hypertriglyceridemia
[18F] FlutemetamolPhase 3Healthy
MEN1703Phase 2Acute Myeloid Leukemia
Pyridoxamine DihydrochloridePhase 2Diabetic Nephropathy
Statin TherapyPhase 2Hypercholesterolemia
AvacopanPhase 2C3 Glomerulopathy (C3G)
AVM0703Phase 2Lymphoid Malignancies
MBN-101Phase 2Bacterial Infection
lerodalcibepPhase 3Heterozygous Familial Hypercholesterolemia
Cefepime -/AAI101Phase 2Urinary Tract Infections
PritelivirPhase 3HSV Infection
dalcetrapibPhase 3Acute Coronary Syndrome
CXA-10Phase 2Primary Focal Segmental Glomerulosclerosis
LIB003Phase 2LDL Cholesterol
cefepime/AAI101 combinationPhase 3Urinary Tract Infections
Cefepime-zidebactam (FEP-ZID)Phase 3Complicated Urinary Tract Infection
rugonersenPhase 3Angelman Syndrome
MultiStemPhase 2Ischemic Stroke
EtripamilPhase 2Paroxysmal Supraventricular Tachycardia (PSVT)
Price & technical context
3-month
+2.1%
6-month
+47.4%
12-month
+7.4%
52-wk range
$393.42–$692.68
vs 50-day MA
-0.0%
vs 200-day MA
+18.9%
Realized vol
45.9%
Max drawdown
-36.6%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MEDP (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.